{"schema_version":"secwatch.filing_event.v1","accession":"0001185185-21-001785","form_type":"8-K","ticker":"IGC","cik":"0001326205","company_name":"IGC Pharma, Inc.","filed_at":"2021-12-02T23:59:59+00:00","discovered_at":"2026-05-14T18:04:12.101038+00:00","generated_at":"2026-06-28T04:05:26.215950+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"IGC Phase 1 trial for THC-based Alzheimer's drug IGC-AD1 shows statistically significant NPI reductions; no SAEs","bullets":["Mean NPI decreased from baseline 31.5 to 16.7 on day 10 (p=0.0044) in Cohort 1; improvements in agitation, anxiety, appetite disorders.","No serious adverse events or deaths across all cohorts; only one related AE (mild dizziness) reported.","IGC plans to design a larger multi-site Phase 2/3 trial pending FDA approval for IGC-AD1.","Sixty-two percent of participants had CYP2C9 intermediate metabolizer phenotype, affecting THC half-life (5.09 h vs 1.73 h for normal)."],"urls":{"canonical":"https://secwatch.observer/filing/0001185185-21-001785","json":"https://secwatch.observer/filing/0001185185-21-001785.json","markdown":"https://secwatch.observer/filing/0001185185-21-001785.md","text":"https://secwatch.observer/filing/0001185185-21-001785.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326205/000118518521001785/0001185185-21-001785-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326205/000118518521001785/indiaglob20211130_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T04:05:26.215950+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}